AVEG 015

A Phase I, Randomized, Double-Blind, Clinical Trial to Compare the Safety and Immunogenicity or Recombinant Envelope Protein, SF-2 rgp120/HIV-1 (Biocine), Individually Combined with Seven Adjuvants, in Healthy HIV-1 Uninfected Individuals

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) June 07, 1993
rgp120/HIV-1 SF-2 Env gp120 B SF-2
rgp120/HIV-1 SF-2 Protein
USA 112